mirabegron (Myrbetriq)
Jump to navigation
Jump to search
Introduction
FDA-approved June 2012
Indications
- treatment of overactive bladder
Contraindications
Dosage
- 25-50 mg P QD
Tabs: 25, 50 mg
Pharmacokinetics
- inhibits CYP2D6
Adverse effects
- hypertension
- nasopharyngitis
- urinary tract infection
- constipation
- fatigue
- tachycardia
- abdominal pain
- not associated with increased risk of cardiac arrhythmia, stroke or myocardial infarction relative to other pharmaceuticals for overactive bladder
- does not affect the CNS & is not associated with cognitive changes
- drug adverse effects of adrenergic receptor agonists
- drug adverse effects of beta-adrenergic receptor agonists
- drug adverse effects of sympathomimetic(s)
Drug interactions
- may increase plasma levels of drugs metabolized by CYP2D6
- increases plasma levels of digoxin
Mechanism of action
- beta-3 adrenergic receptor agonist
- relaxes the bladder muscle during filling, thus increasing bladder storage capacity
Notes
- cost ~ $210/month in 2012
More general terms
Component of
References
- ↑ FDA News Release: June 28, 2012 FDA approves Myrbetriq for overactive bladder http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310096.htm
- ↑ Prescriber's Letter 19(10): 2012 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=281026&pb=PRL (subscription needed) http://www.prescribersletter.com CHART: Medications for Overactive Bladder
- ↑ Tadrous M, Matta R, Greaves S et al Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older - A Population-Based Cohort Study. JAMA Intern Med. Published online July 15, 2019. JAMA Intern Med. Published online July 15, 2019. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2737915